[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367005-105":59,"doc-detail-367005-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sarcoma-in-patients-with-systemic-lupus-erythematosus-a-systematic-review","Sarcoma in patients with systemic lupus erythematosus - A systematic review","","The risk of neoplasms is elevated in autoimmune diseases, and systemic lupus erythematosus (SLE) shows a slightly increased overall cancer incidence. Standardized incidence ratios for several malignancies exceed 3.0, driven by immune dysfunction from the disease and by immunosuppressive medications. Common cancers in SLE link to latent viral infections, including human herpesvirus 8, Epstein-Barr virus, and human papillomavirus. Sarcoma risk remains uncertain, since large cohort data are limited, and case reports suggest possible associations with SLE.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sarcoma-in-patients-with-systemic-lupus-erythematosus-a-systematic-review/367005/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sarcoma-in-patients-with-systemic-lupus-erythematosus-a-systematic-review/367005.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What factors are suggested to drive neoplasm development in SLE patients?","Question",{"text":112,"@type":113},"The document describes immune system dysregulation from SLE and the oncogenic potential of immunosuppressive therapy as two main proposed risk factors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is overall cancer risk in SLE characterized compared with the general population?",{"text":117,"@type":113},"The overall risk is only slightly elevated, with standardized incidence ratio estimates typically between about 1.2 and 2.6 in cited studies, and often below 2.0.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the relationship between sarcoma and SLE considered uncertain?",{"text":121,"@type":113},"Large cohort studies have not consistently established sarcoma risk, while available evidence relies on limited numbers of cases and findings that may reflect chance in small groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367005,1790195225,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review paper Reumatologia 2026; 64, 2: 139–150  \nDOI: [https://doi.org/10.5114/reum/209383](https://doi.org/10.5114/reum/209383)  \nSarcoma in patients with systemic lupus erythematosus. A systematic review  \nWojciech Wołyniec1  􀀌, Mariusz Szajewski2 , Dariusz Nałęcz3   \n1Department of Occupational, Metabolic and Internal Diseases, Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland  \n2Department of Oncological Surgery, Faculty of Health Sciences with the Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland  \n3Department of Otolaryngology and Maxillofacial Surgery, St. Vincent De Paul Hospital, Pomeranian Hospitals, Gdynia, Poland  \nAbstract  \nThe risk of neoplasm is elevated in patients with various autoimmune diseases. Although the overall risk of cancer in systemic lupus erythematosus (SLE) patients is slightly elevated, the standardized incidence ratio of several cancers is above 3.0. The main risk factor for neoplasm in this group is dysfunction of the immune system caused by the disease and by immunosuppressive drugs. The most common cancers in patients with SLE are related to viral latent infections caused by human herpesvirus 8, Epstein-Barr virus, and human papillomavirus. The risk of sarcoma has not been established in large cohort studies, but several case reports have been published. It remains uncertain whether there is a direct relationship between sarcoma and SLE.  \nWe performed a systematic review of case reports and case series and analyzed the detailed data of 26 SLE patients with sarcoma. The most common sarcomas were Kaposi’s sarcoma and leiomyosarcoma – 2 neoplasms that are potentially related to viral infection.  \nKey words: immunosuppressive therapy, viral infection, autoimmune disease, neoplasm, Kaposi’s sarcoma.  \nIntroduction  \nAn increased risk of neoplasms in patients with autoimmune diseases has been reported in the medical literature since the 1950s. To date, numerous cohort studies have shown that the overall risk of cancers, mainly hematological ones, is elevated in this group [1] . The risk for cancers in systemic lupus erythematosus (SLE) patients is slightly elevated, with the standardized incidence ratio (SIR) estimated to be between 1.2 and 2. 6, although in most studies SIR was below 2.0 [2, 3] . For comparison, after kidney transplantation in graft recipients with or without SLE, SIR was estimated to be about 3.5 [4] .  \nTwo main risk factors for neoplasm in SLE have been proposed: immune system dysregulation caused by autoimmune disease, and immunosuppressive therapy [3, 5, 6] . Immune system dysfunction can explain the appearance  \nof neoplasms in the early phase of the disease, when immunosuppressive therapy had yet not been initiated or when the duration of this treatment was short and the cumulative dose of immunosuppressant drugs was relatively low. One disturbing aspect of these cases is the risk of misdiagnosis. In fact, there are several papers describing patients with cancer in whom SLE was a misdiagnosis, or when symptoms of lupus were eventually classified as paraneoplastic syndrome [7, 8] .  \nIt has been suggested that the dysfunction of both the cellular and humoral immune systems can promote oncogenesis in SLE [3, 5, 6, 9] . However, it seems that immunosuppressive treatment is a much stronger risk factor. Drugs used in SLE treatment are well known for their oncogenic potential. For example, cyclophosphamide is responsible for the increased risk of hematological and bladder cancers, and azathioprine for  \nAddress for correspondence  \nWojciech Wołyniec, Department of Occupational, Metabolic and Internal Diseases, Faculty of Health Sciences with the Institute of Maritime  \nand Tropical Medicine, Medical University of Gdansk, 9b Powstania Styczniowego St., 81-519 Gdynia, Poland, [e-mail: wolyniecwojtek@gmail.com](e-mail: wolyniecwojtek@gmail.com)  \n[Submitted:](Submitted: 12.05.2025)[","cbCaiks7IGRChKGg","https://ap.wps.com/l/cbCaiks7IGRChKGg","pdf",117892,12,"English","# Introduction\n## Neoplasm risk in autoimmune diseases\n## Proposed risk factors in SLE\n## Misdiagnosis and paraneoplastic presentation\n# Systemic lupus erythematosus and cancer risk\n## Overall cancer incidence and SIR ranges\n## Variability by cancer type\n# Sarcoma risk in SLE\n## High SIR reports from small observed cohorts\n## Evidence from large studies and case reports","[{\"question\":\"What factors are suggested to drive neoplasm development in SLE patients?\",\"answer\":\"The document describes immune system dysregulation from SLE and the oncogenic potential of immunosuppressive therapy as two main proposed risk factors.\"},{\"question\":\"How is overall cancer risk in SLE characterized compared with the general population?\",\"answer\":\"The overall risk is only slightly elevated, with standardized incidence ratio estimates typically between about 1.2 and 2.6 in cited studies, and often below 2.0.\"},{\"question\":\"Why is the relationship between sarcoma and SLE considered uncertain?\",\"answer\":\"Large cohort studies have not consistently established sarcoma risk, while available evidence relies on limited numbers of cases and findings that may reflect chance in small groups.\"}]","Sarcoma in patients with systemic lupus erythematosus - A systematic review | PDF",1790168795,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5e768b5c79c3789a5ffc61a0e801b1d.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/124674d56f3b3d082dcb2379be984e14.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/177988763caf79d97568e72877730f9f.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c4162a734d89b4142deb111a22dea3e.webp",980,1385]